I Nestorov
Overview
Explore the profile of I Nestorov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mallinckrodt C, Tian Y, Aisen P, Barkhof F, Cohen S, Dent G, et al.
J Prev Alzheimers Dis
. 2023 Mar;
10(2):171-177.
PMID: 36946443
Objectives: Efficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzheimer's disease (AD) have been published. In EMERGE, but not in...
2.
Budd Haeberlein S, Aisen P, Barkhof F, Chalkias S, Chen T, Cohen S, et al.
J Prev Alzheimers Dis
. 2022 May;
9(2):197-210.
PMID: 35542991
Background: Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal...
3.
Shapiro A, Ragni M, Kulkarni R, Oldenberg J, Srivastava A, Quon D, et al.
J Thromb Haemost
. 2014 Sep;
12(11):1788-800.
PMID: 25196897
Background: Routine prophylaxis with replacement factor VIII (FVIII) - the standard of care for severe hemophilia A - often requires frequent intravenous infusions (three or four times weekly). An FVIII...
4.
Rossi J, Moreaux J, Hose D, Requirand G, Rose M, Rouille V, et al.
Br J Cancer
. 2009 Oct;
101(7):1051-8.
PMID: 19789533
Background: Advanced multiple myeloma (MM) and Waldenström's macroglobulinemia (WM) are incurable B-cell malignancies. This is the first full clinical report of atacicept, a fusion protein that binds to and neutralises...
5.
Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A
J Pharm Sci
. 2009 Sep;
99(1):524-38.
PMID: 19743503
Atacicept, a recombinant fusion protein of the TACI receptor and human IgG, is an inhibitor of B-Lymphocyte Stimulator (BLyS) and APRIL, potent stimulators of B cell maturation, proliferation, and survival....
6.
Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, et al.
Lupus
. 2009 Apr;
18(6):547-55.
PMID: 19395457
Atacicept, a recombinant fusion protein containing the extracellular, ligand-binding portion of the transmembrane activator and calcium modulator and cyclophilin-ligand interactor receptor, and the Fc portion of human immunoglobulin (Ig) G,...
7.
Tak P, Thurlings R, Rossier C, Nestorov I, Dimic A, Mircetic V, et al.
Arthritis Rheum
. 2008 Jan;
58(1):61-72.
PMID: 18163485
Objective: Atacicept is a recombinant fusion protein that binds and neutralizes B lymphocyte stimulator and a proliferation-inducing ligand. The purpose of this study was to investigate the tolerability, pharmacokinetics, and...
8.
Nestorov I, Graham G, Duffull S, Aarons L, Fuseau E, Coates P
Pharm Res
. 2001 Oct;
18(8):1210-9.
PMID: 11587494
Purpose: The overall aim of the present study was to investigate retrospectively the feasibility and utility of model-based clinical trial simulation as applied to the clinical development of naratriptan with...
9.
Nestorov I
Toxicol Lett
. 2001 Apr;
120(1-3):411-20.
PMID: 11323201
Two important methodological issues within the framework of the variability and uncertainty analysis of toxicokinetic and pharmacokinetic systems are discussed: (i) modelling and simulation of the existing physiologic variability in...
10.
Peng B, Andrews J, Nestorov I, Brennan B, Nicklin P, Rowland M
Antisense Nucleic Acid Drug Dev
. 2001 Mar;
11(1):15-27.
PMID: 11258618
The aim of this study was to develop a whole body physiologically based model of the pharmacokinetics (PBPK) of the phosphorothioate oligonucleotide (PS-ODN) ISIS 1082 in vivo. Rats were administered...